ORIC Overview

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is19.60 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oric Pharmaceuticals Inc revenue for the last quarter amounts to -34.55M USD, decreased -12.68

Oric Pharmaceuticals Inc. EPS for the last quarter amounts to -22710000.00 USD, decreased -19.68

Oric Pharmaceuticals Inc (ORIC) has 104 emplpoyees as of March 11 2026.

Today ORIC has the market capitalization of 1.41B USD.